Tagged with

Generics Sanjay Singh, General Manager of Torrent in the Philippines, talks about the decision behind entering the Philippine market, the company’s strategy for increasing the influence of Indian pharmaceutical companies in the market, and how Torrent is contributing to the general awareness of patients with schizophrenia and psychosis, conditions that are…

R&D Patrick Tête, Managaing Director of Servier Philippines, speaks about the differences between running the company in Australia and in the Philippines, that the office and company culture is very similar, however, working in a healthcare system exposed to such severe corruption clearly makes the job more complicated in the Philippines.…

Basic Research Despite declining investments by big pharma in recent years, Canada has created a number of innovative ways to incentivize R&D throughout its vast geography. “Science powers commerce,” Canadian Prime Minister Stephen Harper remarked in 2010. In those three words, the prime minister summarizes a massive effort by various stakeholders to…

CEO Talk In the second part of this two-part interview, the chairman of TTY looks back at his experiences in the Taiwanese market, and assess what could have been done differently with his company. He also offers advice to the next generation of Taiwanese pharmaceutical companies. To read the first part of…

Biogenerics The founder and general manager of Biotechnova considers the potential of Colombia for biotechnological innovation, and explains the current state of the biogeneric industry in Latin America. Please start by introducing yourself, and explaining how you came to found Biotechnova. My background is in microbiology and infections: since 2003, there…

DOH Dr. Enrique T. Ona, Secretary of Health, Philippines, speaks about PhilHealth, the ambitious universal healthcare system in the Phillipines, why they have not yet reached the estimated number of beneficiaries, and what needs to be done to tackle the still present problem of the lack of awareness in the poorer…

Array The managing partner, along with two other partners from ByrneWallace discuss the current legal framework in Ireland for small to mid-size companies operating in the pharmaceutical sector. Can you please introduce our readers to yourselves and the firm? Catherine Guy: I’m the current Managing Partner of ByrneWallace—the 7th largest law…

Biotechnology Pedro Ferraz da Costa, CMO Iberfar’s president, discusses generic competition in Portugal, his company’s expansion into Angola and southern Africa, and the company’s competitive advantages with its various subsidiaries. There is some debate whether or not the Portuguese market is a predictable market. From your experience, what is the market’s…

R&D António Portela, CEO of Portugal’s flagship pharmaceutical company Bial, talks about the recent approval of Aptiom by the FDA, the first Portuguese drug to ever to be approved in the US, as well as the unique long-term strategy of the company and the advantages to being a family-run business. Last…

R&D Ramón Palou de Comasema, Country Director of Amgen Portugal, talks about the struggle to enter the reimbursement process in Portugal, how Amgen Portugal has broken this trend by having three of its products reimbursed in the last four years, and further highlights the affiliate’s successes and future growth outlook. How…

partnering David Setboun, Country President of AstraZeneca, discusses the opportunities that the Portuguese market can bring despite economic downturn, and the future of the Portuguese affiliate in expanding to new therapeutic areas. In what way do you think the pharmaceutical industry can act as an engine of economic recovery and development…

R&D Angelini Portugal’s Luigi Cianci offers his critique of the decline of Portugal’s economy and its effects on the industry, talking specifically about the company’s presence in Portugal and its export market—Angelini is one of a few multinationals that produces in conjunction with local facilities. What is your perception of the…